Document Detail


Direct effects of the hypoxic cell sensitizer misonidazole on colony formation in a human tumor cloning assay.
MedLine Citation:
PMID:  3955496     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The human tumor cloning assay as described by Hamburger and Salmon was utilized to study the direct antitumor effects of the hypoxic cell sensitizer misonidazole (MISO). Cells from 106 tumor specimens directly obtained from patients were exposed to MISO at clinically achievable drug concentrations (0.5 mM). Of 30 evaluable tumors, seven specimens (23%) showed a less than or equal to 50% decrease of TCFU's. In vitro sensitivity to MISO was noted in human breast cancer, renal cancer, non small-cell lung cancer, and adenocarcinoma of unknown primary site. A dose response relationship was demonstrated in a subset of experiments including 6 patient's tumors and one human breast cancer cell-line. An analysis relating MISO sensitivity or resistance to the results obtained with other, simultaneously tested standard anticancer drugs indicated that tumors exhibiting a less than or equal to 50% decrease of TCFU's in the presence of MISO were also likely to be sensitive to other cytotoxic drugs. In summary, our data suggest that the 'nitroimidazoles' may exert clinically significant direct antitumor effects in individual tumors. The human tumor cloning assay may have potential to evaluate these direct effects of MISO-analogues and other new radiosensitizers currently being tested in clinical trials.
Authors:
W Scheithauer; D D Von Hoff; B Forseth; J D Cowan
Related Documents :
11518616 - Towards in-vitro prediction of an in-vivo cytostatic response of human tumor cells with...
21505426 - Combined flt3l/tk gene therapy induces immunological surveillance which mediates an imm...
21222006 - Secretory meningiomas: systematic analysis of epidemiological, clinical, and radiologic...
21533576 - Aggressive large cell medulloblastoma extending to the extracranial region in brain-dea...
8528296 - Malignant peripheral neuroectodermal tumors in urology.
16507116 - Intra-articular injection of recombinant trail induces synovial apoptosis and reduces i...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Cancer drug delivery     Volume:  3     ISSN:  0732-9482     ISO Abbreviation:  Cancer Drug Deliv     Publication Date:  1986  
Date Detail:
Created Date:  1986-05-09     Completed Date:  1986-05-09     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  8409965     Medline TA:  Cancer Drug Deliv     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  15-24     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / pharmacology
Colony-Forming Units Assay*
Dose-Response Relationship, Drug
Female
Humans
Male
Misonidazole / pharmacology*
Oxygen
Tumor Stem Cell Assay*
Grant Support
ID/Acronym/Agency:
CA27733-04/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 13551-87-6/Misonidazole; 7782-44-7/Oxygen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A pilot home-based geriatric health screening project in primary care.
Next Document:  131-I coupled to monoclonal antibodies as therapeutic agents for neuroectodermally derived tumors: f...